Ashwani Bahl

Title: Ashwani Bahl: Innovator in Therapeutic Compounds

Introduction

Ashwani Bahl is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of therapeutic compounds, particularly in the development of innovative treatments targeting cyclin-dependent protein kinases (CDKs). His work is crucial in addressing various disorders, including cancer and neurodegenerative diseases.

Latest Patents

Ashwani Bahl holds a patent for a compound titled "4-[[[7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use." This invention focuses on H-APPAMP compounds that selectively inhibit CDK12 and/or CDK13, which are essential in various cellular processes. The compounds not only inhibit these CDKs but also act as selective Cyclin K degraders, enhancing their therapeutic potential. The patent outlines the use of these compounds in treating disorders associated with CDK activity, including cancer, viral infections, and neurodegenerative disorders.

Career Highlights

Ashwani Bahl is currently associated with Carrick Therapeutics Limited, where he continues to advance his research in therapeutic innovations. His work has positioned him as a key figure in the development of new treatments that target critical pathways in disease progression.

Collaborations

He collaborates with esteemed colleagues, including Edward Ainscow and Mihiro Sunose, to further enhance the impact of his research. Their combined expertise contributes to the innovative approaches being developed at Carrick Therapeutics Limited.

Conclusion

Ashwani Bahl's contributions to the field of therapeutic compounds exemplify the importance of innovation in medicine. His work not only addresses significant health challenges but also paves the way for future advancements in treatment options.